source
- Regeneron posts positive phase 2 data for baloncibart in nervous system disorder, eyes pivotal trialRegeneron has posted positive phase 2 data on baloncibart in postural orthostatic tachycardia syndrome, teeing the biotech up to start a potentially pivotal trial in the first half of 2027.
- American Cancer Society updates prostate cancer screening guidanceFor the first time in 16 years the American Cancer Society (ACS) has updated its guideline for prostate cancer screening as it drives to boost detection of the disease before it spreads.Fierce Biotech · 7h ago↗ source
- Pfizer secures up to $1.5 billion from Blackstone to fund berobenatide obesity drug development